Atrial Fibrillation and Stroke in Cancer Patients

C. R. Manrique; J. C. Plana

doi:10.1016/B978-0-12-802509-3.00019-4

Atrial Fibrillation and Stroke in Cancer Patients

C. R. Manrique, J. C. Plana

Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Atrial fibrillation (AF) has a significant impact on our society. Currently, this disease is considered a growing epidemic in the world with an estimated 33.5 million cases worldwide in 2010, and the expectation for the number of cases to rise by at least 5% per year. In the same way, the number of patients with AF in the United States is expected to grow from 2.3 million in 2001 to 5.6-6.3 million in 2050. An epidemiological study conducted by Colilla et al. shows an incidence of 1.2 million cases in 2010, with a statistical projection to 2.6 million in 2030. Similar data have been reported in Europe with an estimated prevalence of AF in the general population of approximately 1.5-2% with an elevated economic cost for the healthcare systems. However, the dimension of the real problem could be underestimated in the light of subclinical disease.

Original language	English (US)
Title of host publication	Anticancer Treatments and Cardiotoxicity
Subtitle of host publication	Mechanisms, Diagnostic and Therapeutic Interventions
Publisher	Elsevier Inc.
Pages	131-138
Number of pages	8
ISBN (Print)	9780128025093
DOIs	https://doi.org/10.1016/B978-0-12-802509-3.00019-4
State	Published - 2017

Keywords

Atrial
Cancer
Fibrillation
Patients
Stroke

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-802509-3.00019-4

Cite this

@inbook{3f84a6de2bb9433ca9e573b2c56706a1,

title = "Atrial Fibrillation and Stroke in Cancer Patients",

abstract = "Atrial fibrillation (AF) has a significant impact on our society. Currently, this disease is considered a growing epidemic in the world with an estimated 33.5 million cases worldwide in 2010, and the expectation for the number of cases to rise by at least 5% per year. In the same way, the number of patients with AF in the United States is expected to grow from 2.3 million in 2001 to 5.6-6.3 million in 2050. An epidemiological study conducted by Colilla et al. shows an incidence of 1.2 million cases in 2010, with a statistical projection to 2.6 million in 2030. Similar data have been reported in Europe with an estimated prevalence of AF in the general population of approximately 1.5-2% with an elevated economic cost for the healthcare systems. However, the dimension of the real problem could be underestimated in the light of subclinical disease.",

keywords = "Atrial, Cancer, Fibrillation, Patients, Stroke",

author = "Manrique, {C. R.} and Plana, {J. C.}",

year = "2017",

doi = "10.1016/B978-0-12-802509-3.00019-4",

language = "English (US)",

isbn = "9780128025093",

pages = "131--138",

booktitle = "Anticancer Treatments and Cardiotoxicity",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Atrial Fibrillation and Stroke in Cancer Patients

AU - Manrique, C. R.

AU - Plana, J. C.

PY - 2017

Y1 - 2017

N2 - Atrial fibrillation (AF) has a significant impact on our society. Currently, this disease is considered a growing epidemic in the world with an estimated 33.5 million cases worldwide in 2010, and the expectation for the number of cases to rise by at least 5% per year. In the same way, the number of patients with AF in the United States is expected to grow from 2.3 million in 2001 to 5.6-6.3 million in 2050. An epidemiological study conducted by Colilla et al. shows an incidence of 1.2 million cases in 2010, with a statistical projection to 2.6 million in 2030. Similar data have been reported in Europe with an estimated prevalence of AF in the general population of approximately 1.5-2% with an elevated economic cost for the healthcare systems. However, the dimension of the real problem could be underestimated in the light of subclinical disease.

AB - Atrial fibrillation (AF) has a significant impact on our society. Currently, this disease is considered a growing epidemic in the world with an estimated 33.5 million cases worldwide in 2010, and the expectation for the number of cases to rise by at least 5% per year. In the same way, the number of patients with AF in the United States is expected to grow from 2.3 million in 2001 to 5.6-6.3 million in 2050. An epidemiological study conducted by Colilla et al. shows an incidence of 1.2 million cases in 2010, with a statistical projection to 2.6 million in 2030. Similar data have been reported in Europe with an estimated prevalence of AF in the general population of approximately 1.5-2% with an elevated economic cost for the healthcare systems. However, the dimension of the real problem could be underestimated in the light of subclinical disease.

KW - Atrial

KW - Cancer

KW - Fibrillation

KW - Patients

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85027275383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027275383&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802509-3.00019-4

DO - 10.1016/B978-0-12-802509-3.00019-4

M3 - Chapter

AN - SCOPUS:85027275383

SN - 9780128025093

SP - 131

EP - 138

BT - Anticancer Treatments and Cardiotoxicity

PB - Elsevier Inc.

ER -

Atrial Fibrillation and Stroke in Cancer Patients

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this